Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
For laboratory use only. This product is intended for animal research only and not for use in humans.
The PC3-Red-FLuc-GFP Bioware® Brite Cell Line is a light-producing and fluorescent cell line derived from PC3 human prostate adenocarcinoma. The cells have been stably transduced with the red-shifted firefly luciferase gene from Luciola Italica (Red-FLuc) fused to GFP (Green Fluorescent Protein), for a brighter, red-shifted bioluminescent or green fluorescent signal.
This cell line has very bright bioluminescence, emitting at least 8,000 photons/cell/sec in vitro. The exact number will vary depending on imaging and culturing conditions.
By emitting intensified, longer wavelength light that is significantly brighter than other firefly luciferases, our bioluminescent oncology cell lines allow you to visualize and monitor the growth of deep tissue tumors in vivo. The GFP fusion also allows for fluorescent imaging in vivo or ex vivo.
After the cells are injected into an appropriate mouse model, the optimized Red-FLuc luciferase enables more sensitive in vivo optical detection with less tissue attenuation so you can detect tumor development earlier, and monitor tumor growth and metastases in both subcutaneous and orthotopic models.
|Oncology Cell Line||Prostate|
|Product Brand Name||Bioware Brite|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Dry Ice|
|Unit Size||2 million cells|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.